Ionis Pharmaceuticals to Present Key Data on Olezarsen at AHA

Ionis Pharmaceuticals, Inc. announced that it will present detailed findings from its pivotal Phase 3 CORE and CORE2 studies of olezarsen during a late-breaking session at the American Heart Association (AHA) Scientific Sessions. This session, titled “Groundbreaking Trials in Cardiometabolic Therapeutics,” will take place in New Orleans, highlighting significant advancements in the treatment of severe hypertriglyceridemia (sHTG).

The CORE and CORE2 studies are crucial in assessing the efficacy of olezarsen, a novel therapeutic approach targeting sHTG, a condition characterized by elevated triglyceride levels that can lead to serious cardiovascular issues. The data presented is expected to provide insights into the drug’s potential benefits and safety profile for patients suffering from this condition.

Ionis Pharmaceuticals, based in Carlsbad, California, is at the forefront of developing innovative treatments for various diseases, with a focus on genetic medicines. The presentation at the AHA Scientific Sessions, scheduled for November 2025, underscores the company’s commitment to advancing cardiometabolic health solutions.

As the medical community gathers in New Orleans, the late-breaking session promises to be a significant platform for discussing cutting-edge research and developments in cardiometabolic therapeutics. Attendees can expect to hear from leading experts in the field, who will analyze the implications of the CORE and CORE2 data on clinical practice.

The AHA Scientific Sessions serve as a critical venue for researchers, clinicians, and industry leaders to share knowledge and foster collaboration aimed at improving patient outcomes. The presentation from Ionis Pharmaceuticals is anticipated to make a notable impact on ongoing discussions surrounding treatment options for severe hypertriglyceridemia.

The data shared during this session is expected to contribute to a deeper understanding of olezarsen’s role in managing sHTG, potentially leading to new therapeutic strategies that can reduce cardiovascular risk for affected individuals. As the conference approaches, the excitement surrounding the findings highlights the ongoing need for effective treatments in the realm of cardiometabolic health.